Source-grounded facts extracted from TherapeuticsMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..
“On December 14, 2021, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Hugh O’Dowd, the Company’s President, as the Company’s Chief Executive Officer”
J. Martin Carroll resigned as director at TherapeuticsMD, Inc..
“On December 13, 2021, Mr. J. Martin Carroll notified TherapeuticsMD, Inc., a Nevada corporation (the “Company”), of his decision to resign from the board of directors of the Company, effective December 31, 2021.”
Robert G. Finizio was appointed as Vice Chair of the Board of Directors at TherapeuticsMD, Inc..
“Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.”
Hugh O'Dowd was appointed as Director at TherapeuticsMD, Inc..
“Mr. O’Dowd will also be appointed to the Company’s Board of Directors.”
Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..
“Mr. Hugh O’Dowd, the Company’s current President, will succeed Mr. Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, as the Company’s Chief Executive Officer effective on or before December 31, 2021.”
Edward Borkowski departed as Executive Vice President, Operations at TherapeuticsMD, Inc..
“On September 30, 2021, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), and Mr. Edward Borkowski, Executive Vice President, Operations of the Company, mutually agreed that Mr. Borkowski would separate from the Company, effective as of such date.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.